GlassScriptPhysician profile
Bruce K Miller
NPI 1689638694
$4,332.11
in general payments reported to CMS, 2019-2025
19 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $30.97 · 2021: $535 · 2022: $482 · 2023: $996 · 2024: $1,385 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.01 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $711.43 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $643.67 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Gilead Sciences, INC. | $581.27 | 2019-2023 | Vemlidy, Sunlenca |
| Astrazeneca Pharmaceuticals LP | $392.82 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $295.15 | 2021-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $201.73 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $158.97 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.36 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $71.39 | 2025 | Rexulti |
| Novo Nordisk INC | $65.66 | 2025 | Wegovy, Saxenda |
| Stryker Corporation | $41.65 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Nestle Healthcare Nutrition INC. | $41.61 | 2020-2021 | |
| Pinnacle, INC | $19.50 | 2025 | |
| Qiagen, LLC | $18.95 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.10 | 2024 | |
| Exact Sciences Corporation | $16.13 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $15.89 | 2025 | Rexulti |
| Indivior INC. | $15.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.